Tenofovir Disoproxil Fumarate and severity of COVID-19 in people with HIV infection
Miguel A. Hernán(Harvard University), Juan Macı́as(Hospital Universitario de Valme), Alfonso Cabello(Hospital Universitario Fundación Jiménez Díaz), José Ramón Arribas(Hospital Universitario La Paz), Inmaculada Jarrín(Instituto de Salud Carlos III), Carlos Dueñas(Hospital Clínico Universitario de Valladolid), Asunción Díaz(Instituto de Salud Carlos III), AI Mariño(Spanish Clinical Research Network), Marta Montero, Santiago Camara(McGill University), Elisa Martínez(University Hospital and Clinics), Santiago Moreno(Universidad El Bosque), Rosa Polo(Ministry of Health), Adrián Curran(Lexington City Schools), JA Iribarren(Biogipuzkoa Health Research Institute)
Cited by 3
Related Papers
Vitamin D intake and incidence of multiple sclerosis
|Neurology|2004|1.1k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Observational Studies Analyzed Like Randomized Experiments
|Epidemiology|2008|814
Activated Injectable Vitamin D and Hemodialysis Survival
|Journal of the American Society of Nephrology|2005|784